Title Page

The impact of COVID-19 pandemic on bronchiolitis (lower respiratory tract infection)

due to respiratory syncytial virus: A systematic review and meta-analysis

Sasidharanpillai Sabeena[1*]**,** Nagaraja Ravishankar[2], S Robin[3]**,** Sabitha Sasidharan Pillai[4]

Article type: **Systematic review and meta-analysis**

Short title: RSV activity during the COVID-19 pandemic

1.Dr Sasidharanpillai Sabeena*,

MBBS, DGO, PhD

Allure Residency, Jhamsikhel,

Lalitpur,

Kathmandu, Nepal-44600

Email: sabeenauthradam@gmail.com

Phone-+977-9808187821

ORCID: https://orcid.org/0000-0002-2099-9312

2. Nagaraja Ravishankar [2]

MSc, PhD

Assistant Professor

Department of Biostatistics

Vallabhbhai Patel Chest Institute

University of Delhi

Vijay Nagar Marg, Art Faculty, University Enclave,

New Delhi, Delhi 110007, India

Email: ravi8133@gmail.com

ORCID: https://orcid.org/ **0000-0002-9533-039X**

3. Dr Sudandiradas Robin [3]

MPH

Research Officer

Manipal Institute of Virology

Manipal Academy of Higher Education

Email: robinnaturedoc@gmail.com

ORCID: https://orcid.org/0000-0002-4340-9434

4 Dr Sabitha Sasidharan Pillai[4]

MBBS, DCH, DNB

Paediatric Endocrinology Fellow,

Warren Alpert Medical School of Brown University, Providence,

593 Eddy Street, Providence, RI 02903, USA

Email id: sabitha_sasidharan_pillai@brown.edu

https://orcid.org/0000-0002-0391-3759

Corresponding Author name:

[1]Dr Sasidharanpillai Sabeena

MBBS, DGO, PhD

Allure Residency, Jhamsikhel,

Lalitpur,

Kathmandu, Nepal-44600

Email id:sabeenauthradam@gmail.com

Phone no: +977-9808187821

https://orcid.org/0000-0002-2099-9312

Abstract

Background: The COVID-19 pandemic has changed the epidemiology of RSV infection which

accounts for most bronchiolitis and viral pneumonias in infants

Aim: This systematic review and meta-analysis aimed to quantitatively evaluate the effect of

the COVID-19 pandemic on respiratory syncytial virus (RSV) associated bronchiolitis among

hospitalised infants.

Methods

The study protocol was registered in the PROSPERO database (CRD42022314000) and was

designed based on PRISMA guidelines updated in May 2020. The meta-analysis component

was modified appropriately to synthesise the pooled proportion of infants having RSV-

associated bronchiolitis before the COVID-19 pandemic in 2019 and during the pandemic

with 95% confidence interval (CI).

Results:

The eight qualified studies from Europe and China, including 109,186 symptomatic cases of

bronchiolitis before the pandemic in 2019 and 61,982 cases in 2020-2021 were pooled by

random-effects meta-analysis. The quantitative analysis included laboratory-confirmed RSV

infection in 7691 infants with bronchiolitis reported before the pandemic in 2019.

Meanwhile, during the pandemic, 4964 bronchiolitis cases were associated with RSV

infection. The pooled proportion of RSV-associated bronchiolitis cases before the pandemic

in 2019 was 16.74% (95% CI 11.73, 22.43%). The pooled proportion of confirmed RSV

cases during the pandemic in 2020/2021 was 19.20 % (95% CI 12.01, 27.59%).

Conclusion

There was an increase in RSV activity after the relaxation of stringent public health measures

during the COVID-19 pandemic.

Keywords: bronchiolitis, COVID-19, pandemic, respiratory syncytial virus, SARS-CoV-2

The impact of COVID-19 pandemic on bronchiolitis (lower respiratory tract infection)
due to respiratory syncytial virus: A systematic review and meta-analysis

Introduction

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a highly infectious novel

coronavirus that emerged in late 2019, leading to the coronavirus disease 2019 (COVID-19)

pandemic. The non-pharmaceutical interventions such as masking, use of hand sanitisers and

various public health measures of lockdowns, travel restrictions, social distancing, isolation,

and quarantines helped to control the transmission in the initial months. Compared to the pre-

pandemic seasons, the epidemiology of other common viral respiratory infections was

significantly affected during the pandemic[1]. There was a decrease in respiratory viral

infections, including respiratory syncytial virus (RSV), due to various non-pharmaceutical

interventions implemented to curb the pandemic. These public health measures reduced the

transmission of enveloped viruses such as influenza and (RSV)[2]. Lower respiratory tract

infections or bronchiolitis in infants lead to increased hospitalisations and mortality during

the winter season. The primary aetiology of bronchiolitis is infection by RSV, which results

in recurrent wheeze and asthma in childhood[3]. Most of the bronchiolitis cases occur in low-

income countries with limited RSV surveillance, which demands molecular diagnostic

facilities. Over the past year, not a single RSV case was reported in many countries during

the winter season, which extended between the last months of 2020 and early 2021. Many

developed countries in the northern and southern hemispheres reported an unexpected surge

in the RSV cases during the summer of 2021[4].

COVID-19 pandemic has led to alterations in the epidemiology of RSV infection which

accounts for most bronchiolitis and viral pneumonias in infants. During the spring or summer

seasons, a resurgence in areas reporting a meagre number of RSV cases was noted globally

during the pandemic. Monitoring the effect of COVID-19 on the circulation of RSV infection

in infants is essential as there are no specific vaccines or antivirals for this virus. This

systematic review and meta-analysis aimed to analyze the effect of the COVID-19 pandemic

on RSV-associated bronchiolitis among hospitalised infants.

Methods

This systematic review was commenced after excluding registered or ongoing systematic

reviews regarding the impact of the COVID-19 pandemic on bronchiolitis (lower respiratory

tract infection) due to respiratory syncytial virus in the PROSPERO database. The study

protocol was registered in the PROSPERO database (CRD42022314000) and can be accessed

at https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42022314000.

The systematic review and meta-analysis were performed based on the Preferred Reporting

Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines updated in May

2020[5]. The meta-analysis component was modified appropriately to synthesise the pooled

proportion of paediatric bronchiolitis cases tested positive for RSV before the COVID-19

pandemic in 2019 and during the pandemic.

Description of the condition

Bronchiolitis: Bronchiolitis is the most common lower respiratory tract viral infection

caused by RSV among children below two years[6], followed by rhinovirus and human Boca

virus. The main clinical features of bronchiolitis are cough, chest recession or tachypnoea,

crackles on chest auscultation or the first episode of acute wheeze[7].

Extended severe acute respiratory infection (SARI) due to RSV: Symptoms of

cough/shortness of breath within the last ten days necessitating hospitalisation due to RSV is

defined as extended severe respiratory infection due to RSV[8].

RSV infection: RSV infection was confirmed in symptomatic cases by real-time reverse transcription polymerase chain reaction (RT-PCR), immunofluorescence assay or virus isolation.

2 Study Protocol

An electronic search of PubMed/MEDLINE, Scopus and Google Scholar was carried out for all the articles in English published between January 2020 and March 2022 regarding the impact of the COVID-19 pandemic on bronchiolitis or lower respiratory tract infection due to the respiratory syncytial virus using search terms such as "impact" AND "COVID-19" OR "SARS-CoV-2" AND "RSV" NOT "vaccines". The manual library search for articles published in peer-reviewed journals was carried out. The references of retrieved articles were examined to increase the search sensitivity.

3 Inclusion process and criteria

Observational studies in English reporting the number of immunocompetent paediatric cases aged two years or below having bronchiolitis or lower respiratory tract infection due to RSV infection were included. Conference abstracts and commentaries were excluded. The studies reporting the data among older children and adults were eliminated. The articles reporting the RSV activity among immunocompromised cases were also not considered.

4 Data extraction

A validated proforma detailing the name of the first author, year of publication, study area, number of cases with bronchiolitis/lower respiratory tract infection (LRTI) attended the hospitals in 2019 and during the pandemic, number of laboratory-confirmed RSV positive cases in 2019 and during the pandemic was prepared. A three-stage selection of published articles was carried out for the final inclusion. One reviewer evaluated the titles of the records for the relevance for inclusion in the study (n=5479). Studies applicable for the review were

moved to the second stage after eliminating irrelevant topics and duplicates (n=5290). In the

second stage, the abstracts of the studies were obtained and were independently examined by

two reviewers (n=97). After reviewing the abstracts, full texts of studies were procured,

which were inspected by two reviewers independently (n=50). The corresponding authors

were communicated electronically if further clarification was needed. Manual library

searches for articles in peer-reviewed journals were carried out, and references of retrieved

articles were reviewed to increase the search sensitivity. The PRISMA 2020 flow diagram[5]

(**Fig 1**) depicts the study selection process. The last date of the search was on March 22,

2022.

5 Risk of bias (quality) assessment in individual studies

To assess the risk of bias in individual studies (quality assessment), chosen after the abstract

and content review, the National Institutes of Health checklist for observational, cohort and

cross-sectional studies was used[9]. The studies with a minimum score of eight or above,

seven, or five or less than five "Yes responses" were considered good, fair, and poor quality,

respectively. For cross-sectional studies, question numbers 1, 2, 3, 4, 5 and 11 were

applicable. The responses to the remaining eight questions (6-10, 12, 13, 14) were not

applicable (NA). The studies with six "Yes" responses were considered good, and those with

four /five were taken as fair. The studies with less than four "Yes responses" were considered

poor quality. The quality of the studies was evaluated by two reviewers independently.

6 Statistical analysis

The meta-analysis was accomplished in STATA version 13.0 (College Station, Texas 77, 845

USA). The forest plots were constructed using metaprop package in STATA. The pooled

proportion of symptomatic cases of RSV-associated bronchiolitis or lower respiratory tract

infections before the pandemic in 2019 and during the pandemic was reported with 95% CI.

Chi-square statistic (Q statistic) and I^2 index to quantify the heterogeneity was noted as

considerable heterogeneity across the studies was expected. The I² value ranging between 0%

to 24% specifies consistency. I² values of 25%-49% imply low heterogeneity and 50-74%

points toward moderate heterogeneity. The I² value varying between 75%-100% is indicative

of high heterogeneity[10].

7 Assessment of Publication bias

Egger's test was used to report the publication bias. Weighted linear regression with

standardised effect estimate and precision was considered the dependent and independent

variables, respectively. In the present study, the $\log_e$ proportion of RSV positive bronchiolitis

cases and precision were considered the effect estimate and 1/standard error of $\log_e$

proportion rate, respectively. Weights were allotted using the inverse variance approach

(1/variance of the effect estimate). A statistically significant bias coefficient is the evidence

for publication bias.

Results

Included studies

We identified and screened 189 articles and fifty full texts were systematically reviewed. The

eight qualified studies for the meta-analysis were from Spain, Italy, France and China,

including 109,186 symptomatic cases of bronchiolitis before the pandemic in 2019 and

61,982 cases during the pandemic[11–18]. All these studies were qualified, as good as shown

in **Table 1**. These studies reported 7691 laboratory-confirmed RSV associated lower

respiratory tract infections in 2019 and 4964 during the pandemic in 2020/21. Two studies

from Spain and France were multicenteric [16,18]. The highest number of symptomatic cases

were admitted in the multicentric study from Spain[16] before the pandemic in 2019 and

during the pandemic. All the studies chosen for the meta-analysis reported a decrease in

bronchiolitis cases with increased RSV positivity during the pandemic. The highest RSV

positivity in bronchiolitis was 70.2% before the pandemic. Meanwhile, during the COVID-19

pandemic, RSV was the causative agent in up to 77.8% of bronchiolitis cases, as in Table 1.

Meta-analysis

The pooled proportion of RSV-associated bronchiolitis cases before the pandemic in 2019

was 16.74% (95% CI 11.73%,22.43%) as in **Fig 2**. **Fig 3** represents the pooled proportion of

RSV cases among infants during the pandemic in 2020/2021, as 19.20% (95% CI

12.01%,27.59%). As the I^{2}-value was>90%, high heterogeneity was observed between the

studies.

Publication bias

As shown in **Table 2,** the *p*-value for the bias coefficient was not statistically significant.

Hence there was no publication bias.

Discussion

The studies qualified for this meta-analysis were from China and Europe. The pooled

proportion of RSV positivity in bronchiolitis cases was more during the COVID-19

pandemic, even though a decline in bronchiolitis cases or lower respiratory tract infections

was observed during the COVID-19 pandemic. Many countries such as Italy, Germany,

Belgium, Vienna and Brazil reported no hospitalised bronchiolitis cases during the winter

season[12,19–21]. Similarly, the study from Israel reported a temporal shift of RSV epidemic

to spring season from winter[22]. During the COVID-19 pandemic, hospitals in Spain

reported a steep decline in bronchiolitis cases and RSV positivity with seven months delayed

RSV peak in July 2021[16]. Meanwhile, France reported a rise in RSV cases during the late

winter months of 2021 after the second national lockdown in December 2020 [15]. Japan

observed no reporting of RSV cases in 2020, followed by a resurgence in July 2021[23]. The

tropical country of Thailand, located in South East Asia, witnessed a delayed RSV season in

2020 among children with influenza-like illness[24]. There was an increase in the number of

confirmed RSV cases across all age groups during the spring season of the year 2020 in

Australia and South Africa[25,26]. The inter-seasonal rise in RSV infections during the

summer was observed in the northern and southern hemispheres[27,28]. Italy reported a

significant decline in hospitalised cases of bronchiolitis in 2020, with no bronchiolitis cases

in 2021. However, a late RSV peak was not observed in Italy, unlike many countries[12]. In

2020, China reported a decrease in lower respiratory tract infection among children, mainly

due to the strict public health measures to contain the SARS-CoV-2 infection. The studies

from Shanghai and Xiamen reported a decline in RSV activity among the hospitalised

children. Both the studies observed a mild increase in RSV and influenza activity during the

winter months without a temporal shift in seasonality[14,29]. However, another single centre

study from Hangzhou reported a marked rise in RSV cases during the winter season of 2020,

comparable to the pre-pandemic period[17].

Respiratory viral infections at young age facilitate the building up of trained immunity. Apart

from a relatively young population of Africa compared to other parts of the world, prior

exposure to other cross-reactive viruses is another causative factor for low SARS-CoV-2

related morbidity and mortality in Sub-Saharan Africa[30]. However, countries perceiving a

very low number of RSV cases are at an increased risk of resurgence of RSV infection,

mainly among older RSV-naïve children[31]. Sentinel surveillance of RSV is better in many

European countries than in other parts of the world[32,33]. There is no data regarding the

RSV activity from the majority of the Asian and African countries having higher RSV

associated disease burden [34].

Causes of heterogeneity

The main heterogeneity was in the number of bronchiolitis cases enrolled before and during

the pandemic. Two multicentric studies enrolled a higher number of hospitalised cases

compared to single centre studies. Even though six studies confirmed RSV infection by RT-

PCR, two studies from China detected the RSV infection by direct immunofluorescence

assay, which is less sensitive[35]. Another disparity was in the time of the year during which

the samples were procured from paediatric bronchiolitis cases. Although six studies enrolled

infants below one year, two studies incorporated cases below two years.

Limitation

Before the COVID-19 pandemic, there was no routine testing of bronchiolitis samples for

RSV from developing countries in South East Asia, Africa and Latin America. All the studies

included in the meta-analysis were from Europe and China. Even though there were studies

from other parts of the world reporting low RSV activity among infants during the COVID-

19 pandemic, very few studies reported RSV positivity. The studies pertaining to RSV

surveillance from the US, Germany and South Africa could not be included for meta-analysis

as adults and children were sampled for RSV surveillance [26,36–39].

During the coming seasons, health care professionals and hospitals must be prepared to

manage the increasing number of symptomatic RSV cases. Our systematic review will be

beneficial for European Union funded PROMISE project initiated in November 2021 which

aims RSV surveillance and immunisation in Europe[40]. This review emphasises the

importance of promoting RSV maternal vaccines and passive childhood immunisation with

monoclonal antibodies (mAbs).

Conclusion

295 There was an increase in RSV activity after relaxing stringent public health measures during

296 the COVID-19 pandemic in the northern and southern hemispheres. Efforts for the diagnosis

297 and surveillance for RSV must be reinforced along with influenza and SARS-CoV-2 viruses

298 to minimise the burden of hospitalisation and mortality among infants.

References

1. Britton PN, Hu N, Saravanos G, Shrapnel J, Davis J, Snelling T, et al. COVID-19 public health measures and respiratory syncytial virus. Lancet Child Adolesc Health 2020;4:e42–3. doi: 10.1016/S2352-4642(20)30307-2

2. Takashita E, Kawakami C, Momoki T, Saikusa M, Shimizu K, Ozawa H, et al. Increased risk of rhinovirus infection in children during the coronavirus disease-19 pandemic. Influenza Other Respir Viruses 2021;15:488–94. doi: 10.1111/irv.12854

3. Blanken MO, Rovers MM, Molenaar JM, Winkler-Seinstra PL, Meijer A, Kimpen JLL, et al. Respiratory Syncytial Virus and Recurrent Wheeze in Healthy Preterm Infants. New England Journal of Medicine 2013 9;368:1791–9. doi: 10.1056/NEJMoa1211917

4. Williams TC, Sinha I, Barr IG, Zambon M. Transmission of paediatric respiratory syncytial virus and influenza in the wake of the COVID-19 pandemic. Eurosurveillance 2021 22;26:2100186. doi: 10.2807/1560-7917.ES.2021.26.29.2100186

5. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021 29;372:n71. doi: 10.1136/bmj.n71

6. Kenmoe S, Kengne-Nde C, Ebogo-Belobo JT, Mbaga DS, Modiyinji AF, Njouom R. Systematic review and meta-analysis of the prevalence of common respiratory viruses in children < 2 years with bronchiolitis in the pre-COVID-19 pandemic era. PLOS ONE 2020 12;15:e0242302. doi: 10.1371/journal.pone.0242302

7. NICE. Bronchiolitis in children: diagnosis and management [Internet]. London: National Institute for Health and Care Excellence (NICE); 2021 [cited 2022 3]. doi: http://www.ncbi.nlm.nih.gov/books/NBK573086/

8. WHO. Case definitions [Internet]. [cited 2021 7];doi: https://www.who.int/teams/control-of-neglected-tropical-diseases/yaws/diagnosis-and-treatment/global-influenza-programme

9. Study Quality Assessment Tools | NHLBI, NIH [Internet]. [cited 2020 27];doi: https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools

10. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003 6;327:557–60. doi: 10.1136/bmj.327.7414.557

11. Guitart C, Bobillo-Perez S, Alejandre C, Armero G, Launes C, Cambra FJ, et al. Bronchiolitis, epidemiological changes during the SARS-CoV-2 pandemic. BMC Infectious Diseases 2022 24;22:84. doi: 10.1186/s12879-022-07041-x

12. Stera G, Pierantoni L, Masetti R, Leardini D, Biagi C, Buonsenso D, et al. Impact of SARS-CoV-2 Pandemic on Bronchiolitis Hospitalizations: The Experience of an Italian Tertiary Center. Children (Basel) 2021 28;8:556. doi: 10.3390/children8070556

13. Curatola A, Lazzareschi I, Bersani G, Covino M, Gatto A, Chiaretti A. Impact of COVID-19 outbreak in acute bronchiolitis: Lesson from a tertiary Italian Emergency Department. Pediatr Pulmonol 2021;56:2484–8. doi: 10.1002/ppul.25442

14. Liu P, Xu M, Cao L, Su L, Lu L, Dong N, et al. Impact of COVID-19 pandemic on the prevalence of respiratory viruses in children with lower respiratory tract infections in China. Virol J 2021 3;18:159. doi: 10.1186/s12985-021-01627-8

15. Fourgeaud J, Toubiana J, Chappuy H, Delacourt C, Moulin F, Parize P, et al. Impact of public health measures on the post-COVID-19 respiratory syncytial virus epidemics in France. Eur J Clin Microbiol Infect Dis 2021;40:2389–95. doi: 10.1007/s10096-021-04323-1

16. Torres-Fernandez D, Casellas A, Mellado MJ, Calvo C, Bassat Q. Acute bronchiolitis and respiratory syncytial virus seasonal transmission during the COVID-19 pandemic in Spain: A national perspective from the pediatric Spanish Society (AEP). J Clin Virol 2021;145:105027. doi: 10.1016/j.jcv.2021.105027

17. Ye Q, Liu H. Impact of non-pharmaceutical interventions during the COVID-19 pandemic on common childhood respiratory viruses - An epidemiological study based on hospital data. Microbes Infect 2022;24:104911. doi: 10.1016/j.micinf.2021.104911

18. Casalegno J-S, Ploin D, Cantais A, Masson E, Bard E, Valette M, et al. Characteristics of the delayed respiratory syncytial virus epidemic, 2020/2021, Rhône Loire, France. Eurosurveillance 2021 22;26:2100630. doi: 10.2807/1560-7917.ES.2021.26.29.2100630

19. Diesner-Treiber SC, Voitl P, Voitl JJM, Langer K, Kuzio U, Riepl A, et al. Respiratory Infections in Children During a Covid-19 Pandemic Winter. Front Pediatr 2021;9:740785. doi: 10.3389/fped.2021.740785

20. Van Brusselen D, De Troeyer K, Ter Haar E, Vander Auwera A, Poschet K, Van Nuijs S, et al. Bronchiolitis in COVID-19 times: a nearly absent disease? Eur J Pediatr 2021;180:1969–73. doi: 10.1007/s00431-021-03968-6

21. Varela FH, Scotta MC, Polese-Bonatto M, Sartor ITS, Ferreira CF, Fernandes IR, et al.
Absence of detection of RSV and influenza during the COVID-19 pandemic in a
Brazilian cohort: Likely role of lower transmission in the community. J Glob Health
2021 1;11:05007. doi: 10.7189/jogh.11.05007

22. Weinberger Opek M, Yeshayahu Y, Glatman-Freedman A, Kaufman Z, Sorek N,
Brosh-Nissimov T. Delayed respiratory syncytial virus epidemic in children after
relaxation of COVID-19 physical distancing measures, Ashdod, Israel, 2021. Euro
Surveill 2021;26. doi: 10.2807/1560-7917.ES.2021.26.29.2100706

23. Ujiie M, Tsuzuki S, Nakamoto T, Iwamoto N. Resurgence of Respiratory Syncytial
Virus Infections during COVID-19 Pandemic, Tokyo, Japan. Emerg Infect Dis
2021;27:2969–70. doi: 10.3201/eid2711.211565

24. Thongpan I, Vichaiwattana P, Vongpunsawad S, Poovorawan Y. Upsurge of human
rhinovirus infection followed by a delayed seasonal respiratory syncytial virus infection
in Thai children during the coronavirus pandemic. Influenza and Other Respiratory
Viruses 2021;15:711–20. doi: 10.1111/irv.12893

25. Zheng Z, Pitzer VE, Shapiro ED, Bont LJ, Weinberger DM. Estimation of the Timing
and Intensity of Reemergence of Respiratory Syncytial Virus Following the COVID-19
Pandemic in the US. JAMA Netw Open 2021 16;4:e2141779. doi:
10.1001/jamanetworkopen.2021.41779

26. Tempia S, Walaza S, Bhiman JN, McMorrow ML, Moyes J, Mkhencele T, et al.
Decline of influenza and respiratory syncytial virus detection in facility-based
surveillance during the COVID-19 pandemic, South Africa, January to October 2020.
Euro Surveill 2021;26. doi: 10.2807/1560-7917.ES.2021.26.29.2001600

27. Saravanos GL, Hu N, Homaira N, Muscatello DJ, Jaffe A, Bartlett AW, et al. RSV
Epidemiology in Australia Before and During COVID-19. Pediatrics 2022
27;149:e2021053537. doi: 10.1542/peds.2021-053537

28. Respiratory Syncytial Virus (RSV) in Florida | Florida Department of Health [Internet].
[cited 2022 2];doi: https://www.floridahealth.gov/diseases-and-conditions/respiratory-
syncytial-virus/

29. Wang J, Xiao T, Xiao F, Hong S, Wang S, Lin J, et al. Time Distributions of Common
Respiratory Pathogens Under the Spread of SARS-CoV-2 Among Children in Xiamen,
China. Front Pediatr 2021 12;9:584874. doi: 10.3389/fped.2021.584874

30. Njenga MK, Dawa J, Nanyingi M, Gachohi J, Ngere I, Letko M, et al. Why is There
Low Morbidity and Mortality of COVID-19 in Africa? The American Journal of
Tropical Medicine and Hygiene 2020 1;103:564–9. doi: 10.4269/ajtmh.20-0474

31. Foley DA, Phuong LK, Peplinski J, Lim SM, Lee WH, Farhat A, et al. Examining the
interseasonal resurgence of respiratory syncytial virus in Western Australia. Arch Dis
Child 2022;107:e7. doi: 10.1136/archdischild-2021-322507

32. Mollers M, Barnadas C, Broberg EK, Penttinen P, Teirlinck AC, Fischer TK. Current
practices for respiratory syncytial virus surveillance across the EU/EEA Member States,

2017. Euro Surveill 2019 3;24:1900157. doi: 10.2807/1560-
7917.ES.2019.24.40.1900157

33. Teirlinck AC, Broberg EK, Berg AS, Campbell H, Reeves RM, Carnahan A, et al.
Recommendations for respiratory syncytial virus surveillance at national level.
European Respiratory Journal [Internet] 2021 1 [cited 2022 18];doi:
https://erj.ersjournals.com/content/early/2021/02/11/13993003.03766-2020doi:
10.1183/13993003.03766-2020

34. Broor S, Campbell H, Hirve S, Hague S, Jackson S, Moen A, et al. Leveraging the
Global Influenza Surveillance and Response System for global respiratory syncytial
virus surveillance-opportunities and challenges. Influenza Other Respir Viruses
2020;14:622–9. doi: 10.1111/irv.12672

35. Shafik CF, Mohareb EW, Youssef FG. Comparison of Direct Fluorescence Assay and
Real-Time RT-PCR as Diagnostics for Respiratory Syncytial Virus in Young Children.
Journal of Tropical Medicine 2011 14;2011:e781919. doi: 10.1155/2011/781919

36. Olsen SJ. Changes in Influenza and Other Respiratory Virus Activity During the
COVID-19 Pandemic — United States, 2020–2021. MMWR Morb Mortal Wkly Rep
[Internet] 2021 [cited 2022 1];70. doi:
https://www.cdc.gov/mmwr/volumes/70/wr/mm7029a1.htmdoi:
10.15585/mmwr.mm7029a1

37. Groves HE, Piché-Renaud P-P, Peci A, Farrar DS, Buckrell S, Bancej C, et al. The
impact of the COVID-19 pandemic on influenza, respiratory syncytial virus, and other
seasonal respiratory virus circulation in Canada: A population-based study. The Lancet
Regional Health – Americas [Internet] 2021 1 [cited 2021 6];1. doi:
https://www.thelancet.com/journals/lanam/article/PIIS2667-193X(21)00007-
7/fulltextdoi: 10.1016/j.lana.2021.100015

38. Park KY, Seo S, Han J, Park JY. Respiratory virus surveillance in Canada during the
COVID-19 pandemic: An epidemiological analysis of the effectiveness of pandemic-
related public health measures in reducing seasonal respiratory viruses test positivity.
PLoS One 2021;16:e0253451. doi: 10.1371/journal.pone.0253451

39. Oh D-Y, Buda S, Biere B, Reiche J, Schlosser F, Duwe S, et al. Trends in respiratory
virus circulation following COVID-19-targeted nonpharmaceutical interventions in
Germany, January - September 2020: Analysis of national surveillance data. Lancet Reg
Health Eur 2021;6:100112. doi: 10.1016/j.lanepe.2021.100112

40. Promise-FactSheet-03-1.pdf [Internet]. [cited 2022 3];doi: https://imi-promise.eu/wp-
content/uploads/Promise-FactSheet-03-1.pdf

Statements and Declarations

a. Funding: This study was not funded

b. Conflicts of interests/competing interests:

The authors have no relevant financial or non-financial interests to disclose.

c. Availability of Data:

The preprint was published in medRxiv (https : // www. medrxiv. org/ content /10.1101 /2022.04.26.22274244v1) on 27th April. The data that support the findings of this study are available from the corresponding author upon reasonable request (Dr Sasidharanpillai Sabeena, sabeenauthradam@gmail.com).

d. ETHICS STATEMENT

The authors state that this manuscript does not involve any misconduct such as plagiarism, forgery, tampering, improper signature, multiple submission, repeated publication, split publication, etc. The systematic review and meta☐analysis used published data in indexed journals. Ethical approval to conduct the analysis was not sought as this was a secondary data analysis that requires no approval. No data with a personal identifier was used.

e. Author Contributions: All authors contributed to the study conception and design. Material preparation, data collection and analysis were performed by Sasidharanpillai Sabeena, N Ravishankar, Sudandiradas Robin and Sabitha Sasidharanpillai. The first draft of the manuscript was written by Sasidharanpillai Sabeena and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

g. Consent to participate (include appropriate statements): Not Applicable

h. Consent for publication (include appropriate statements): Not Applicable

Figure Captions

Fig 1. PRISMA 2020 flow diagram for updated systematic reviews which included searches
of databases, registers and other sources. The flow diagram illustrates the number of studies
identified, screened, abstracts/full-text articles included/excluded for the systematic review
and meta-analysis.

Fig 2. The Forest Plot of the summary effect size (Proportion of bronchiolitis cases tested
positive for RSV before the COVID-19 pandemic) using random-effects model. Squares
indicate the effect size of individual studies and the extended lines denote 95% confidence
intervals (CI). Sizes of squares imply the weight of studies based on sample size using a
random effects analysis. The diamond data indicates pooled prevalence. Test of
heterogeneity: $I^{2=}$ 99.62%, p-value=0.00

Fig 3. The Forest Plot of the summary effect size (Proportion of RSV positive bronchiolitis
cases during the COVID-19 pandemic) using random-effects model. Squares indicate the
effect size of individual studies and the extended lines denote 95% confidence intervals (CI).
Sizes of squares imply the weight of studies based on sample size using a random effects
analysis. The diamond data indicates pooled prevalence. Test of heterogeneity: $I^{2=}$ 99.69 %,
p=0.00.

Table 1 Characteristics of the studies included for the meta-analysis

S No	Reference (year)	Region	Study design	Study site	Age in months	LRTI/ bronchiolitis before the pandemic	Duration	RSV Positivity N(%)	LRTI/ bronchiolitis during the pandemic	Duration	RSV Positivity N (%)	Diagnosis	Quality of the study
1	Guitart et al 2022[11]	Barcelona Spain	Prospective observational	Single centre	<12	124	2019-20	87 (70.2)	63	2020-21	49 (77.8)	RT-PCR	Good
2	Stera et al[12] 2021	Bologna Italy	retrospective observational	Single centre	≤12	114	Oct 2018-April2019	75 (65.8)	98	2019/2020 Oct-April	72 (73.5)	RT-PCR	Good
3	Curatola et al 2021[13]	Rome Italy	retrospective observational	Single centre	≤24	238	2019 Feb-2020 Feb	40 (16.8)	33	2020 Feb-2021 Feb	6 (18.2)	RT-PCR	Good
4	Liu et al Aug 2021[14]	Shanghai China	retrospective observational	Single centre	≤12	4600	2019	304 (6.6)	2507	2020	114 (4.5)	Multiplex Direct IFA	Good
5	Fourgeaud et al 2021[15]	France	retrospective observational	Single centre	≤11	5396	Aug2019-July 2020	172 (3.2)	4804	2020/21-Aug-April	169 (3.5)	RT-PCR	Good
6	Torres-Fernandes et al 2021[16]	Spain	retrospective observational	multicentric	≤24	82,577	2019	5936 (7.2)	42,924	2020	3912 (9.1)	RT-PCR	Good
7	Ye et al[17]	Hangzhou China	retrospective observational	Single centre	≤12	7010	2019	953 (!3.6)	2825	2020	565 (20.0)	Multiplex Direct IFA	Good
8	Casalegno et al 2021[18]	Lyon France	retrospective observational	multicentric	≤12	9,127	2019/20 Sept-May	124 (1.35)	8,728	2020/21 Sept-May	77 (0.88)	RT-PCR	Good

Table 2: The table depicts the results of Egger's test for publication bias

Results of Egger's test (Before the Pandemic)		
Coefficient	Estimate (95%CI)	P-value
Slope	0.0532 (0.0067, 0.0997)	0.051
Bias	2.9071 (-2.5261,8.3403)	0.238
Results of Egger's test (after the Pandemic)		
Slope	0.0605 (-0.0093, 0.1304)	0.449
Bias	2.4388 (-3.7147,8.5924)	0.370